| Name | Title | Contact Details |
|---|
Targacept`s clinical pipeline is built on a unique class of therapeutic targets.
United Biomedical, Inc. (UBI) is an international bio/pharmaceutical firm with cutting edge technology utilizing reverse genomics and synthetic peptide chemistry, coupled with traditional pharmaceutical and therapeutic delivery systems. The company has
Girindus America is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.
Hospria is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.